Caricamento...
Lutetium Lu-177 Dotatate Flare Reaction
PURPOSE: Lutetium Lu-177 dotatate is the first peptide receptor radionuclide therapy approved by the US Food and Drug Administration. Well-designed studies in Europe have shown dramatic effectiveness in improving progression-free survival in patients with gastroenteropancreatic neuroendocrine tumors...
Salvato in:
| Pubblicato in: | Adv Radiat Oncol |
|---|---|
| Autori principali: | , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Elsevier
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7811111/ https://ncbi.nlm.nih.gov/pubmed/33490736 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.adro.2020.11.008 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|